New Orleans - Psoriatic patients achieving >75 percentreduction in PASI score with one course of alefacept (Amevive) followedby treatment-free follow-up maintained >50 percent reduction for at leasteight months.
SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
DPCP Immunotherapy Yields 61.8% Hair Regrowth Rate in Pediatric Alopecia Areata
“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema